Mugisho, O.O.; Aryal, J.; Shome, A.; Lyon, H.; Acosta, M.L.; Green, C.R.; Rupenthal, I.D.
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. Int. J. Mol. Sci. 2023, 24, 3876.
https://doi.org/10.3390/ijms24043876
AMA Style
Mugisho OO, Aryal J, Shome A, Lyon H, Acosta ML, Green CR, Rupenthal ID.
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences. 2023; 24(4):3876.
https://doi.org/10.3390/ijms24043876
Chicago/Turabian Style
Mugisho, Odunayo O., Jyoti Aryal, Avik Shome, Heather Lyon, Monica L. Acosta, Colin R. Green, and Ilva D. Rupenthal.
2023. "Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy" International Journal of Molecular Sciences 24, no. 4: 3876.
https://doi.org/10.3390/ijms24043876
APA Style
Mugisho, O. O., Aryal, J., Shome, A., Lyon, H., Acosta, M. L., Green, C. R., & Rupenthal, I. D.
(2023). Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences, 24(4), 3876.
https://doi.org/10.3390/ijms24043876